This article was downloaded by: [Computing & Library Services, University of Huddersfield] On: 04 January 2015, At: 02:54 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn19

Synthesis and Properties of 2'-O-Methylribonucleotide Methylphosphonate Containing Chimeric Oligonucleotides

Ekambar R. Kandimalla^a, Jamal Temsamani^a & Sudhir Agrawal^a ^a Hybridon, Inc., One Innovation Drive, Worcester, MA, 01605, USA Published online: 16 Feb 2007.

To cite this article: Ekambar R. Kandimalla , Jamal Temsamani & Sudhir Agrawal (1995) Synthesis and Properties of 2'-O-Methylribonucleotide Methylphosphonate Containing Chimeric Oligonucleotides, Nucleosides and Nucleotides, 14:3-5, 1031-1035

To link to this article: <u>http://dx.doi.org/10.1080/15257779508012527</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions

SYNTHESIS AND PROPERTIES OF 2'-O-METHYLRIBONUCLEOTIDE METHYLPHOSPHONATE CONTAINING CHIMERIC OLIGONUCLEOTIDES

Ekambar R. Kandimalla, Jamal Temsamani and Sudhir Agrawal Hybridon, Inc., One Innovation Drive, Worcester, MA 01605, USA.

Abstract: 2'-O-methylribonucleoside methylphosphonamidites are synthesized and incorporated into oligonucleotides to obtain chimeric antisense oligonucleotides. The resulting oligonucleotide binds to their target RNA/DNA sequences efficiently and stable in a medium containing bovine serum.

Oligonucleotides (oligos) and their analogs have wide applicability in diagnostics, molecular biology and therapeutics development^{1,2}. Antisense oligos were shown to be active against several targets *in vitro* and *in vivo*³. In order to improve cellular uptake and nuclease resistance several sugar and phosphate backbone modified oligos have been synthesized and studied^{2,4}. In addition to deoxyribonucleotide analogs oligoribonucleotides have also been explored for antisense uses as they bind to an RNA target more tightly than their DNA counterpart⁵. To increase the nuclease resistance phosphorothioate analogs of RNA have been synthesized and studied⁶. However, synthesis of non-ionic methylphosphonate or methylphosphotriester oligoribonucleotides is difficult due to the unstability of such compounds because of the presence of a hydroxyl group at the 2'-position⁷. An alternative way to make oligoribonucleotides resistant to RNase is by alkylation of the 2'-hydroxyl group⁸. Synthesis of a dimer of 2'-Omethylribonucleotide methylphosphonates was reported⁹. Recently, a preliminary report on 2'-O-methyl-ribonucleoside methylphosphonates was published¹⁰.

Now we have developed a synthetic route for the preparation of 2'-O-methylribonucleoside methylphosphonamidates (2) and their incorporation into oligonucleotides. The resulting new oligos containing 2'-O-methylribonucleoside analogs were examined for



Scheme 1. Scheme for the synthesis of 3'-phoshonamidites (2) and subsequent incorporation into oligos. a: $CH_3-P(Cl)-N-i-Pr_2$ and diisopropyl ethylamine; b: Dichloroacetic acid; c: Tetrazole; and d: $I_2/H_2O/THF/Lutidine mixture$. B could be any 2'-O-methylribonucleoside base (A, C, G or U). The new chemical modification is shown in square bracket for clarity.

exonuclease resistance, hybridization efficiency with target nucleic acids and *in vitro* translation inhibition.

The chimeric oligo (3) [5'-d(CTCTCGCACCCATCTCTCTC)C*U*U*C*d(T); * indicates 2'-O-methylribonucleoside methylphosphonate] and control oligo (4) [5'd(CTCTCGCACCCATCTCTCTCTTCT)] used in the study are complementary to the initiation codon region of gag RNA of HIV-1. The synthesis of 2'-O-methylribonucleoside phosphonamidites was carried out as detailed in Scheme 1. In principle, the procedure was based on the reported method for the synthesis of deoxyribonucleoside phosphonamidites and their incorporation into oligos^{11,12}. The required 5'-O-dimethoxytrityl (DMT)-3'hydroxy-2'-O-methylribonucleosides (1) were converted to 3'-O-methyl-N,N-diisopropylaminophosphonamidites (2) by treating 1 with methyl diisopropylchlorophosphonamidite in the presence of diisopropyl ethylamine. The overall yields of C and U methylphosphonamidites (2) ranged from 65-72% based on starting material 1. These synthons were used on the DNA synthesiser to be introduced at required positions in oligos. The average coupling yields were >97%, which is comparable to the average coupling yields obtained in the synthesis of oligodeoxyribonucleoside methylphosphonates. The rest of the oligo sequences were assembled using standard protocols for β -cyanoethyl phosphoramidite chemistry. After the completion of synthesis, oligos were deprotected and purified^{11,12}.

The incorporation of the methylphosphonate linkages into the oligos was examined by ion exchange HPLC¹² and it was confirmed that the oligo **3** has four charges less than oligo **4** as deduced from retention times. This suggests that the incorporation of the modified monomers does not prevent subsequent addition and extension of the oligo chain. The thermal melting study of the modified 25 mer, **3** with complementary nucleic acid strands demonstrated efficient hybridization with both RNA and DNA targets¹³. Typical melting curves are shown in figure 1. The oligo **3** gave Tms of 68.7 and 63.7°C with RNA and DNA complementary strands, respectively. Under the same conditions the unmodified control oligo **4** showed Tms of 71.8 and 65.7°C with RNA and DNA complementary strands, respectively. The lower Tm values of 2-3°C obtained with the new oligo **3** compared to the control oligo **4** with both the target nucleic acids could be due to decreased concentration of the binding species because of the presence of nonbinding S_p-diastereomers arising from the methyl substitution on phosphate¹⁴. This indicates



Figure 1. Melting curves of chimeric (3) and control (4) oligos with A: DNA, and B: RNA complementary strands in 10 mM disodium hydrogen phosphate, pH 7.4 and 100 mM sodium chloride buffer.

that the new modification introduced in the oligo does not substantially destabilise the duplex formed between the oligo and its complementary RNA or DNA target. The % hyperchromicity values obtained with oligo 3 (15 and 19.2 with RNA and DNA strands respectively) compared to the unmodified oligo 4 duplex (18.1 and 22.3 with RNA and DNA strands respectively) further confirmed the validity of the Tm values obtained.

The presence of the 2'-Omethylribonucleoside methylphosphonate group at the 3'-end confers stability to the oligo against exonucleases. The normal oligo 4

was digested to half of its initial concentration $(T_{1/2})$ in about 100 seconds by snake venom phosphodiesterase (SVPD), a 3'-exonuclease¹². However, the $T_{1/2}$ of the oligo 3 was measured to be up to 800-900 seconds under the same experimental conditions. This indicates that the modification is resistant to the exonuclease action. A more comprehensive way to examine oligo stability in vitro is by incubating in serum. The stability of oligos 3 and 4 in 10% fetal bovine serum¹⁵ at different time intervals is shown in figure 2. The majority of the oligo 3 was intact up to 4 hours compared to the control oligo 4. densometric analysis The of the autoradiogram showed that more than 95% of the unmodified oligo 4 was digested by bovine serum nucleases within one hour. However, at least 40-50% of the oligo 3 with four modifications at 3'-end was intact Figure 2. Stability of the oligos 3 and 4 in for up to 4 hours.



cell culture medium containing of 10% fetal bovine serum.

The ability to inhibit translation in a cell free system by oligos 3 and 4 was studied¹⁵. In wheat germ extract, containing RNase H, both of the oligonucleotides arrested protein synthesis compared to the control. The results showed 10-15% higher inhibition with unmodified oligo 4 than with the modified oligo. This result correlates well with the lower duplex stability of oligo 3 observed in melting studies. However, increased stability to nucleases is more critical in the in vivo rather than in vitro situation .

We conclude that the synthesis of 2'-O-methylribonucleoside methylphosphonate oligos can be carried out using an automated DNA synthesizer. The oligo containing this modification hybridizes to both RNA and DNA single strand targets efficiently, has increased stability in cell culture medium containing 10% fetal bovine serum and inhibits translation in vitro. Currently we are investigating the cellular pharmacology and gene regulation activity of oligo 3 and similar oligos against HIV-1.

REFERENCES

- Zamecnik, P.C. (1991) In Wickstrom, E. (ed.), Prospets for Antisense Nucleic Acid 1. Therapy of Cancer and AIDS. Wiley-Liss, New York, pp 1-6.
- Uhlmann, E. & Peyman, A. (1990) Chem. Rev. 90, 543-584; Helene, C. & 2. Tolume, J.J., Biochim. Biophys. Acta (1990) 1049, 99-125.
- Stein, C.A. & Chang, Y.-C. (1993) Science, 261, 1004-1012; Agrawal, S. (1992) 3. TIBTech. 10. 152-158.
- Milligan, J.F., Matteucci, M.D. & Martin, J.C. (1993) J. Med. Chem. 36, 1923-4. 1937.
- Shibahara, S., Mukai, S., Morisawa, H., Nakashima, H., Kobayashi, S. & 5. Yamamoto, N. (1989) Nucleic Acids Res. 17, 239-252.

- Agrawal, S., Tang, J.-Y., Sun, D., Sarin, P.S. & Zamecnik, P.C. (1992) Ann. N.Y. Acad.Sci. 660, 2-10.
- Gait, M.J. (1993) In Crook, S.T. & Lebleu, B.(Eds.), Antisense Research and Applications. CRC Press, Boca Raton, Florida, pp 289-301.
- 8. Lamond, A.I. & Sproat, B.S. (1993) FEBS Lett. 325, 123-127.
- Quaedflieg, P.J.L.M., van der Heiden, A.P., Koole, L.H., Coenen, A.J.J., van der Wal, S. & Meijer, E.M. (1991) J. Org. Chem. 56, 5846.
- Miller, P.S., Bhan, P., Cushman, C.D., Kean, J.M. & Levis, J.T. (1991) Nucleosides and Nucleotides 10, 37-46.
- Agrawal, S. & Goodchild, J. (1987) Tetr. Lett. 28, 3539-3542. The phosphonamidites were characterised by ³¹P NMR.
- 12. Padmapriya, A.A. & Agrawal, S. (1993) BioMed. Chem. Lett. 3, 761-764.
- 13. Kandimalla, E.R. & Agrawal, S.(1994) Gene (in press).
- Hausheer, F.H., Rao, B.G., Saxe, J.D. & Singh, U.C. (1992) J. Am. Chem. Soc. 114, 3201-3206; Giles, R.V. & Tidd, D.M. (1992) Anticancer Drug Des. 7, 37-48.
- 15. Ghosh, M.K., Ghosh, K. & Cohen, J.S. (1993) Anticancer Drug Des. 8, 15-32.